<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Epstein-Barr virus (EBV)-immortalized human B cells survive only transiently when injected subcutaneously into athymic mice, whereas Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells give rise to progressively growing subcutaneous <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we tested whether these <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt's tumors</z:e> could be induced to regress via a bystander effect induced by EBV-immortalized B cells </plain></SENT>
<SENT sid="2" pm="."><plain>Simultaneous inoculation of EBV-immortalized B cells and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells in the same subcutaneous site resulted in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumors</z:e> that regressed with <z:mp ids='MP_0001651'>necrosis</z:mp> and <z:hpo ids='HP_0100699'>scarring</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Similarly, simultaneous inoculation of EBV-immortalized B cells and Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> cells in separate subcutaneous sites resulted in regression of a proportion of the <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt's tumors</z:e> </plain></SENT>
<SENT sid="4" pm="."><plain>Furthermore, most of the established human <z:e sem="disease" ids="C0006413" disease_type="Neoplastic Process" abbrv="BL">Burkitt's tumors</z:e> regressed with <z:mp ids='MP_0001651'>necrosis</z:mp> and <z:hpo ids='HP_0100699'>scarring</z:hpo> after intratumor inoculations with EBV-immortalized B cells </plain></SENT>
<SENT sid="5" pm="."><plain>The EBV-immortalized B cells continued to exert this antitumor effect even when killed with irradiation </plain></SENT>
<SENT sid="6" pm="."><plain>The experimental approach to Burkitt's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> treatment described here exploits the ability of athymic mice to reject EBV-immortalized B cells to target an effective antitumor response to malignant cells normally incapable of eliciting it </plain></SENT>
</text></document>